Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co Analyst Ratings
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $130
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $125
Truist lowers Merck's target price to $132.
Truist lowers Merck's target price to $132.
Merck & Co Analyst Ratings
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Announces Target Price $132
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $136
Truist Financial Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $132
TD Cowen Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck Price Target Cut to $140.00/Share From $142.00 by Barclays
Merck & Co Analyst Ratings
Barclays Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $140
Merck & Co Analyst Ratings
Gritstone Downgraded by Jones, B. Riley Over Cancer Vaccine Data